ES2069424T3 - Metodos para el tratamiento de la osteoporosis. - Google Patents

Metodos para el tratamiento de la osteoporosis.

Info

Publication number
ES2069424T3
ES2069424T3 ES92908494T ES92908494T ES2069424T3 ES 2069424 T3 ES2069424 T3 ES 2069424T3 ES 92908494 T ES92908494 T ES 92908494T ES 92908494 T ES92908494 T ES 92908494T ES 2069424 T3 ES2069424 T3 ES 2069424T3
Authority
ES
Spain
Prior art keywords
treatment
subject
osteoporosis
methods
phosphonate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92908494T
Other languages
English (en)
Inventor
Jocelyn Elaine Mcosker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Chilcott Pharmaceuticals Inc
Original Assignee
Procter and Gamble Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Pharmaceuticals Inc filed Critical Procter and Gamble Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2069424T3 publication Critical patent/ES2069424T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Removal Of Specific Substances (AREA)

Abstract

LOS METODOS DE TRATAMIENTO DE OSTEOPOROSIS EN UN HUMANO U OTRO SUJETO ANIMAL, COMPRENDEN: LA ADMINISTRACION A DICHO SUJETO DE UN FOSFONATO ACTIVADOR OSEO , EN UN NIVEL DE AL MENOS 0.1 LED POR DIA DE TRATAMIENTO, Y LA ADMINISTRACION HA DICHO SUJETO DE UNA HORMONA ESTROGENA EN UN NIVEL DESDE 0.2 HASTA 0.8 LED POR DIA DE TRATAMIENTO. EL FOSFONATO ACTIVADOR OSEO ES PREFERIBLEMENTE UN BIFOSFONATO, O UN FOSFONATO FOSFONOALQUIL.
ES92908494T 1991-02-26 1992-01-31 Metodos para el tratamiento de la osteoporosis. Expired - Lifetime ES2069424T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66177791A 1991-02-26 1991-02-26

Publications (1)

Publication Number Publication Date
ES2069424T3 true ES2069424T3 (es) 1995-05-01

Family

ID=24655074

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92908494T Expired - Lifetime ES2069424T3 (es) 1991-02-26 1992-01-31 Metodos para el tratamiento de la osteoporosis.

Country Status (18)

Country Link
US (1) US6329354B1 (es)
EP (1) EP0573604B1 (es)
JP (1) JP3727332B2 (es)
KR (1) KR100240358B1 (es)
AT (1) ATE119777T1 (es)
AU (1) AU664368B2 (es)
CA (1) CA2101275C (es)
CZ (1) CZ282609B6 (es)
DE (1) DE69201725T2 (es)
DK (1) DK0573604T3 (es)
ES (1) ES2069424T3 (es)
HU (1) HU215124B (es)
IE (1) IE65963B1 (es)
NO (1) NO305581B1 (es)
NZ (1) NZ241717A (es)
RU (1) RU2113848C1 (es)
SK (1) SK90093A3 (es)
WO (1) WO1992014474A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2123666T3 (es) * 1992-03-21 1999-01-16 Entec Aplicacion de estriol para la preparacion de un sistema terapeutico transdermico para tratar la osteoporosis climaterica.
AU4859493A (en) * 1992-10-09 1994-05-09 Upjohn Company, The Pyrimidine bisphosphonate esters and (alkoxymethylphosphinyl)alkyl phosphonic acids as anti-inflammatories
US6399592B1 (en) 1992-12-23 2002-06-04 Merck & Co., Inc. Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
JPH08505142A (ja) * 1992-12-23 1996-06-04 メルク エンド カンパニー インコーポレーテッド 骨損失を治療及び予防するためのビスホスホネート／エストロゲン療法
RU2134103C1 (ru) * 1993-05-15 1999-08-10 Берингер Маннхайм ГмбХ Таблетка с улучшенной биодоступностью биологически активного вещества и вещество, повышающее биодоступность
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
CA2208714C (en) * 1994-12-28 2003-10-21 Gador S.A. Bone mass anabolic composition comprising olpadronate
DE19635883A1 (de) * 1996-09-04 1998-03-05 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einer Östriol enthaltenden Wirkstoffkombination
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
EP0949928A4 (en) * 1996-11-25 2000-09-13 Merck & Co Inc ADMINISTRATED ANDROGENS AND DIPHOSPHONE COMPOUNDS FOR TREATING DISEASES
US6692763B1 (en) * 1998-11-19 2004-02-17 The Regents Of The University Of California Methods for treating postmenopausal women using ultra-low doses of estrogen
AR013994A1 (es) * 1998-10-30 2001-01-31 Gador Sa Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.
EP1057488A4 (en) * 1998-12-25 2003-10-22 Toray Industries INTERLEUKIN-6 PRODUCTION INHIBITORS
US6326365B1 (en) 1999-07-20 2001-12-04 Apollo Biopharmaceutics, Inc. Methods of prevention and treatment of ischemic damage
US6339078B1 (en) 1999-07-20 2002-01-15 University Of Florida Research Foundation, Inc. Methods of prevention and treatment of ischemic damage
US6653298B2 (en) 2000-01-14 2003-11-25 Sterix Limited Composition
US7335650B2 (en) 2000-01-14 2008-02-26 Sterix Limited Composition
US20040038946A1 (en) * 2001-04-27 2004-02-26 Wilson Lon J. Fullerene-based drugs targeted to bone
RU2199273C1 (ru) * 2001-11-05 2003-02-27 Научно-исследовательский институт кардиологии Томского научного центра СО РАМН Способ оценки кровоснабжения грудины после операций на грудной клетке
WO2009068567A1 (en) * 2007-11-30 2009-06-04 Novartis Ag C2-c5-alkyl-imidazole-bisphosphonates
EP2459176B1 (en) 2009-07-31 2017-09-27 Grünenthal GmbH Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3553314A (en) 1968-12-23 1971-01-05 Procter & Gamble Oral compositions for calculus retardation
US3683080A (en) 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
EP0088462A3 (en) * 1982-03-01 1984-06-06 The Procter & Gamble Company Anti-inflammatory and rheumatic composition containing organophosphonate and steroid
ATE114473T1 (de) * 1984-04-30 1994-12-15 Procter & Gamble Ausrüstung für die verwendung bei der behandlung von osteoporose.
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
IL86951A (en) 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
ATE119777T1 (de) 1995-04-15
HUT66429A (en) 1994-11-28
CZ175593A3 (en) 1994-04-13
US6329354B1 (en) 2001-12-11
NZ241717A (en) 1997-02-24
IE920584A1 (en) 1992-08-26
WO1992014474A1 (en) 1992-09-03
DE69201725D1 (de) 1995-04-20
NO305581B1 (no) 1999-06-28
AU664368B2 (en) 1995-11-16
CZ282609B6 (cs) 1997-08-13
NO933044D0 (no) 1993-08-26
RU2113848C1 (ru) 1998-06-27
EP0573604B1 (en) 1995-03-15
HU215124B (hu) 1998-09-28
NO933044L (no) 1993-08-26
SK90093A3 (en) 1994-09-07
CA2101275A1 (en) 1992-08-27
KR100240358B1 (ko) 2000-02-01
JPH06505501A (ja) 1994-06-23
IE65963B1 (en) 1995-11-29
JP3727332B2 (ja) 2005-12-14
EP0573604A1 (en) 1993-12-15
AU1643392A (en) 1992-09-15
CA2101275C (en) 1998-08-04
DE69201725T2 (de) 1996-04-18
HU9302407D0 (en) 1993-11-29
DK0573604T3 (da) 1995-05-29

Similar Documents

Publication Publication Date Title
ES2069424T3 (es) Metodos para el tratamiento de la osteoporosis.
CO4370025A1 (es) Terapia a base de alendronato para prevenir el aflojamiento de dispositivos de implante ortopedico
MX9307569A (es) Formulacion de mezcla seca para acidos bisfosfonicos.
CO4340681A1 (es) Procedimientos de uso para la inhibicion de la perdida osea y la disminucion del colesterol en suero
MX9207349A (es) Metodos para el tratamiento de osteoporosis utilizando bisfosfonatos y hormona de paratiroides.
ES2120993T3 (es) Agentes antitromboticos.
ES2127409T3 (es) Metodo para la modulacion de la respuesta sexual en el hombre.
DE69233559D1 (de) Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten
PT777483E (pt) Metodos e meio para administrar farmacos
ES2058547T3 (es) Fuente organica de fluoruro.
YU39695A (sh) Formulacija analoga insulina
ES2045186T3 (es) Soporte para la planta de los pies.
MX9304432A (es) Compuestos y formulaciones farmaceuticas para el tratamiento o prevencion de la osteoporosis y la perdida de los huesos.
ES2129485T3 (es) Derivados de acidos guanidinoalquil-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion.
ES2032016T3 (es) Un procedimiento para la produccion de las 13, 14-ceto-pgfs.
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
ES2098920T3 (es) Formulaciones farmaceuticas para el tratamiento de la dependencia a la nicotina.
RU93054017A (ru) Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза
ES2023343A6 (es) Mejoras introducidas en la patente de invencion principal n{ 8802234 por dispositivo para un laser de potencia.
ATE161423T1 (de) Verwendung von phosphinate zur behandlung der osteoporose
DE68918099D1 (de) Pharmazeutische behandlung einer augenentwicklung.
ES2058125T3 (es) Derivados de piperidina para el tratamiento del dolor.
ATE84716T1 (de) 4-chinolincarbonsaeure-derivate, brauchbar zur behandlung von haut- und muco-epithelialgewebekrankheiten.
ATE201680T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
BR0013416A (pt) Droga, uso de uma droga selecionada do grupo que consiste de pelo menos um bisfosfonato, e, método para tratamento de um osso fraturado

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 573604

Country of ref document: ES